Anti-tumor activity of F8-LIGHT was tested in two syngeneic murine models of cancer. CT26 and WEHI-164 tumors were implanted in the right flank of BALB/c mice by subcutaneous injection of 3 × 106 and 2.5 × 106 cells, respectively. Treatments were started when tumors reached a volume of about 100 mm3. The indicated dose of immunocytokines or the corresponding volume of saline, were administered by intravenous injection in the lateral tail vein, every other day for a total of three injections. The immune-checkpoint inhibitor anti-PD-1 (BioXCell, clone 29 F.1A12) was administered in the same way, at alternate days. Mice were inspected daily. Body weight was monitored, tumor was measured with a caliper and tumor size was determined using the formula: ½ x (major diameter) x (minor diameter)2. Mice with ulcerated hemorrhagic tumor, or with tumor bigger than 1500 mm3 where euthanized.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.